MedTrace Logo

Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer

NCT05714891 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2026-02-12

No results posted yet for this study

Summary

This study is being done to answer the following question: What are the effects of new treatments on non-small cell lung cancer before surgery?

Conditions

Interventions

DRUG

JDQ443

Dose will be assigned at enrollment

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Jonathan Spicer · McGill University, Montreal, QC Canada

  • Normand Blais · CHUM-Centre Hospitalier de l'Universite de Montreal, QC Canada

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-15
Primary Completion
2026-08-31
Completion
2028-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05714891 on ClinicalTrials.gov